Abstract Environmental or lifestyle factors are likely to explain part of the heterogeneity in breast and ovarian cancer risk among BRCA1 and BRCA2 mutation carriers.
P = 0.9 for women under age 40), and this trend was highly consistently observed for carriers of mutations in each gene. There was no evidence of an association between breast cancer risk and age at first birth for parous BRCA1 or BRCA2 mutation carriers (P-trend C 0.3). The power to detect associations with ovarian cancer risk was much lower, especially for BRCA2 mutation carriers. Nevertheless, having a live-birth was associated with protection for BRCA1 mutation carriers (HR = 0.41, 95%CI = 0.18-0.94, P = 0.03), and a strong and consistent protective effect of age at first birth was observed for parous carriers of mutations in both genes (HR = 0.65, 95%CI = 0.52-0.83, P \ 0.001). This is the third independent study to find that, as in the general population, parity appears to be associated with protection from breast cancer in women with mutations in BRCA1 and BRCA2.
Introduction
The incomplete penetrance of mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 suggests that there are other genetic and/or environmental factors that modify the risk of these cancers in female mutation carriers. Additional evidence of risk modifiers includes the general observation that estimates of penetrance tend to be higher in studies of multiple-case families than in studies of families of cases unselected for family history [1] , as well as the more recent finding that the proportion of breast cancer phenocopies (cases of cancer in non-carrier members of a mutation-carrying family) is greater than that expected according to the disease incidence in the general population [2] [3] [4] . Both results suggest that other genetic and/or non-genetic factors may accumulate in some families and influence the risk of cancer in carriers and non-carriers alike. More specific evidence of the existence of non-genetic modifiers, of breast cancer risk in particular, comes from the consistent observation that the penetrance of BRCA1 and BRCA2 mutations has increased over the last century [1, [5] [6] [7] [8] . Environmental or lifestyle factors, rather than genetic factors, are most likely to explain this trend.
The identification of these risk-modifying factors for mutation carriers is important for several reasons. Firstly, providing these women with information about what they can do with respect to environmental and lifestyle factors to reduce their risk of cancer may be an important complement to screening programs, and a possible alternative to invasive prophylactic surgical interventions. Secondly, the incorporation of these factors into penetrance estimation will lead to more accurate risk modelling and therefore better informed genetic counselling.
It is not clear whether established risk factors for breast and/or ovarian cancer in the general population, such as parity [9, 10] , act as risk modifiers in carriers of mutations in BRCA1 and BRCA2. Various studies have investigated such factors as modifiers, but all are subject to potential biases due to the way in which mutation carriers are recruited, and few definitive conclusions have been reached [11] . While prospective studies of cohorts of unaffected carriers are considered best placed to clarify this issue, these will take time to accumulate a sufficient number of incident cancer cases for analysis. It is therefore important that, at least until results from prospective studies become available, the largely retrospective data at hand are taken advantage of to make appropriate inference. Results that are consistently observed across multiple studies are likely to be most reliable.
It has been established in the general population that an increasing number of children is associated with protection from both breast and ovarian cancer [9, 12, 13] . Later age at first birth is associated with increased risk of breast cancer [9] , but possibly a reduced risk of ovarian cancer [13] . Parity has been evaluated as a breast cancer risk modifier in a number of studies of mutation carriers [14] [15] [16] [17] [18] [19] [20] published studies of modifiers of ovarian cancer risk [15, 21, 22] . We aimed to assess parity (ever parous, number of full-term pregnancies and age at first full-term pregnancy) as a modifier of breast cancer risk and ovarian cancer risk in carriers of mutations in BRCA1 and BRCA2 recruited by 13 genetic counselling centres in Spain.
Methods

Subjects
All female carriers of deleterious mutations in BRCA1 and BRCA2 recruited at 13 genetic counselling centres in Spain (see Table 1 ) were considered eligible. These included: (1) 799 mutation carriers recruited by 12 centres between 1995 and 2006 from the 319 families included in our previous penetrance study [5] ; (2) 235 mutation carriers from 235 families in which, as at 31st December, 2006, they were the only individual that had tested positive (which meant that they were excluded from the penetrance study, [5] Family selection, mutation testing and other data collection methods have been described previously [5] . Briefly, the youngest member affected with breast and/or ovarian cancer from families with multiple cases of these cancers was generally the first tested for mutations in BRCA1 and/or BRCA2. When a mutation was detected, that specific mutation was tested for in additional family members. Mutations were defined as deleterious if they were classified as clinically important by the Breast Information Core (BIC, http://research.nhgri.nih.gov/bic/) or they met other widely accepted criteria [5] . Information c All identified female mutation carriers were considered eligible, but only those with complete data were included in the analyses d Carriers from Vall d'Hebron were not included in the penetrance study [5] . These included 4 of 5 eligible obligate BRCA1 mutation carriers and 1 eligible obligate BRCA2 mutation carrier on year of birth, breast and ovarian cancer status, age at diagnosis of breast and/or ovarian cancer (if applicable), current age, age at death (if deceased), age at prophylactic bilateral mastectomy (if applicable), and age at prophylactic oophorectomy (if applicable), was collected for each family member as part of genetic counselling. We excluded eligible mutation carriers with missing data for any of these items, or for which the year of birth of at least one of their children was unknown.
Statistical methods
We compared the distribution of subjects across centres (CNIO, Sant Pau, HCSC, ICO, Vall d'Hebron, FPGMX, all others combined for BRCA1 mutation carriers; and CNIO, Sant Pau, HCSC, ICO, Valencia, all others combined for BRCA2 mutation carriers) between affected and unaffected mutation carriers using Pearson's chi-squared test. The distributions of age at censoring (see below) and year of birth were compared by affection status using logistic regression, fitting each of these as continuous variables.
Associations with the risk of breast and ovarian cancer were assessed separately for each of the parity variables considered, by estimating hazard ratios (HR) and their corresponding 95% confidence intervals (CI) using weighted multivariable Cox proportional hazards regression with robust estimates of variance [23] . For each mutation carrier, we modelled the time to diagnosis of breast or ovarian cancer from birth, censoring at the first of the following events: bilateral prophylactic mastectomy, bilateral prophylactic oophorectomy, breast cancer diagnosis, ovarian cancer diagnosis, death and date last known to be alive. For the analysis of breast cancer, subjects were considered affected if their age at censoring corresponded to their age at diagnosis of breast cancer and unaffected otherwise. For the analysis of ovarian cancer, subjects were considered affected if their age at censoring corresponded to their age at diagnosis of ovarian cancer and unaffected otherwise. Weights were assigned separately for the breast and ovarian cancer analyses, by affection status, age and gene mutated, so that the weighted observed incidence rate agreed with established estimates [1] , summarized as ''external rates'' in Antoniou et al. [23] . The age categories considered were\25, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, 55-59, 60-64, 65-69 and C70, with the first three categories combined for the ovarian cancer analysis due to the small number of affected women observed. These weights have been shown to correct for the bias inherent in the oversampling of affected women due to the ascertainment criteria applied [23] .
We evaluated associations with parity (nulliparous, parous), number of live-births (0, 1, 2, 3, C4) and age at first live-birth (15-19, 20-24, 25-29 , C30), with trends assessed for the latter two based on the corresponding continuous variables. For the analysis of categories of age at first livebirth, 20-24 was used as the reference group because it was the most common. All these measures were modelled as time-varying variables. Additional independent variables included in all analyses were year of birth (\1930, 1930-1939, 1940-1949, 1950-1959, 1960-1969 , C1970) and centre (as defined above and presented in Table 2 ). Heterogeneity in HRs by age was assessed based on the Waldstatistic P-value corresponding to the interaction term for the variable in question and age (dichotomized into \40, C40). Mutation carriers from the present study included in previous studies of parity as a modifier of cancer risk by the International BRCA1/2 Carrier Cohort Study (IBCCS) [17, 22] were excluded and weights recalculated in sensitivity analysis. The influence of survival bias was evaluated by repeating all analyses (based on recalculated weights) after excluding affected women who were genetically tested more than 3 years after their breast cancer diagnosis, or more than 1 year after their ovarian cancer diagnosis.
All statistical analyses were carried out using Stata: Release 10 [24] . Robust estimates of variance were calculated using the cluster subcommand, applied to an identifier variable unique to each family. All P-values were two-sided and those less than 0.05 were considered statistically significant.
Results
Of the 626 eligible BRCA1 mutation carriers and 604 eligible BRCA2 mutation carriers, 515 (82%) and 503 (83%), respectively, were included in the analyses of parity as a risk modifier. Details are given in Table 1 . These were members of 253 and 246 families, respectively. The distribution of the number of carriers per family were very similar for BRCA1 and BRCA2 mutations, with, overall, 51% of families with just one member, 23% with two, 13% with three, 6% with four, 3% with five, 2% with six, 1% with seven and less than 1% of families with eight or more members represented in the dataset. Table 2 summarises the characteristics of included mutation carriers according to affection status, and gene mutated. For ovarian cancer, but not breast cancer, affected mutation carriers tended to be older than unaffected mutation carriers, regardless of the gene mutated (both P \ 0.001). For carriers of mutations in both genes and for both cancers, affected women tended to be born before unaffected women (all P B 0.001).
Associations with breast cancer risk
Results from the multivariable analysis of the three parity variables and breast cancer risk are summarized in Table 3 . The results for ever being parous and number of live-births were very similar for carriers of mutations in BRCA1 and BRCA2, with HR estimates below 1, although none were statistically significant (all P C 0.08). After combining mutation carriers in both genes, the estimated HR associated with ever having had a live-birth was 0.74 (95% confidence interval [CI] = 0.55-1.01, P = 0.06), and that associated with each live-birth was 0.87 (95%CI = 0.77-0.98, P = 0.02). Analyses stratified by age suggested that this association with number of live-births was only apparent in women aged 40 and above (HR = 0.81, 95%CI = 0.70-0.94, P = 0.004 vs. HR = 0.99, 95%CI = 0.83-1.18, P = 0.9 for women under age 40). While the difference in HR by age was not statistically significant (P = 0.1), this result was consistently observed for BRCA1 mutation carriers (HR = 0.82, 95%CI = 0.69-0.98, P = 0.03 for women aged 40 and above and HR = 1.02, 95%CI = 0.81-1.29, P = 0.9 for younger women) and BRCA2 mutation carriers (HR = 0.81, 95%CI = 0.63-1.04, P = 0.09 and HR = 0.97, 95%CI = 0.74-1.28, P = 0.8, respectively). We observed no evidence of an association between breast (18) 15 (21) 90 (20) 64 (22) 53 (25) 11 (31) 106 (23) Sant Pau 46 (17) 40 (17) 9 (12) 77 (17) 43 (15) 40 (19) 6 (17) 77 (16) HCSC 35 (13) 43 (18) 13 (18) 65 (15) 35 (12) 37 (17) 5 (14) 67 (14) ICO 31 (11) 21 (9) 5 (7) 47 (11) 32 (11) 32 (15) 5 (14) 59 (13) Vall d'Hebron 29 (11) 31 (13) 5 (7) 55 (12) FPGMX 28 (10) 31 (13) 13 (18) 46 (10) Valencia 32 (11) 18 (8) 3 (9) 47 (10) Others a 46 (17) 29 (12) 13 (18) 62 (14) 83 (28) 34 (16) 5 (14) 112 ( (7) 2 (1) 21 (10) 0 (0) 23 (5) 25-29 23 (8) 24 (10) 0 (0) 47 (11) 17 (6) 27 (13) 0 (0) 44 (10) 30-34 54 (20) 34 (14) 6 (8) 82 (19) 44 (15) 36 (17) 1 (3) 79 (17) 35-39 57 (21) 34 (14) 6 (8) 85 (19) 62 (21) 23 (11) 0 (0) 85 (18) 40-44 61 (22) 35 (15) 12 (16) 84 (19) 58 (20) 25 (12) 3 (9) 80 (17) 45-49 36 (13) 28 (12) 17 (23) 47 (11) 44 (15) 23 (11) 5 (14) 62 (13) 50-54 23 (8) 21 (9) 14 (19) 30 (7) 26 (9) 19 (9) 5 (14) 40 (9) 55-59 8 (3) 17 (7) 10 (14) 15 (3) 15 (5) 11 (5) 3 (9) 23 (5) 60-64 3 (1) 7 (3) 2 (3) 8 (2) 10 (3) 12 (6) 10 (29) 12 (3) 65-69 2 (1) 9 (4) 4 (5) 7 (2) 5 (2) 11 (5) 5 (14) 11 (2) cancer risk and age at first birth for parous BRCA1 or BRCA2 mutation carriers (both P-trend C 0.3). There were 67 mutation carriers that were included in a previous study of parity and breast cancer risk by the IBCCS [17] , 38 with mutations in BRCA1 and 29 with mutations in BRCA2. Excluding these made no substantial difference to the results obtained. The estimated HR per live-birth was 0.86 for BRCA1 mutation carriers, 0.90 for BRCA2 mutation carriers and 0.87 (P = 0.03) for all carriers combined. The corresponding HR estimates for women aged less than 40 were 0.96, 1.03 and 0.97, respectively, while those for women aged 40 and above were 0.82, 0.83 and 0.81 (P = 0.008), respectively. There were 299 affected mutation carriers who were diagnosed with breast cancer more than 3 years prior to their mutation testing, 154 with mutations in BRCA1 and 145 with mutations in BRCA2. Excluding these similarly made no substantial difference to the results obtained. The estimated HR per live-birth was 0.77 for BRCA1 mutation carriers, 0.88 for BRCA2 mutation carriers and 0.79 (P = 0.002) for all mutation carriers combined.
Associations with ovarian cancer risk
Results from the multivariable analyses of the three parity variables and ovarian cancer risk are also summarized in Table 3 . For BRCA1 mutation carriers, ever having had a live-birth was associated with reduced risk of ovarian cancer (HR = 0.41, 95%CI = 0.18-0.94, P = 0.03). There was some evidence of a dose-response effect, with BRCA1 mutation carriers with four or more children at even lower estimated risk relative to those with no children (HR = 0.15, 95%CI = 0.04-0.56, P = 0.005), but the trend per birth was not statistically significant (HR = 0.80, 95%CI = 0.61-1.05, P = 0.1). There was no evidence of association with number of live-births for BRCA2 mutation carriers (all P C 0.3). Age at first birth appeared to be inversely associated with ovarian cancer risk, with very similar HR estimates for BRCA1 and BRCA2 mutation carriers (P-trend = 0.001 and 0.1 for BRCA1 and BRCA2 mutation carriers, respectively). The estimated HRs for carries of mutations in both genes combined, per 5 years of age, was 0.65 (95%CI = 0.52-0.83, P \ 0.001).
There were 116 mutation carriers that were included in a previous study of parity and ovarian cancer risk by the IBCCS [22] , 59 with mutations in BRCA1 and 57 with mutations in BRCA2. Excluding these gave slightly stronger evidence of the associations reported above. For BRCA1 mutation carriers the estimated HRs were 0.32 (P = 0.01) for ever having had a live-birth and 0.74 (P = 0.04) per live-birth. The estimated HR associated with increments of 5 years in age at first birth was 0.64 (P = 0.004) for BRCA1 mutation carriers, 0.46 (P = 0.02) for BRCA2 mutation carriers and 0.60 (P = 0.001) for all carriers combined. There were 55 affected mutation carriers who were diagnosed with ovarian cancer more than 1 year prior to their mutation testing, 36 with mutations in BRCA1 and 19 with mutations in BRCA2. Results were consistent after excluding these women. For BRCA1 mutation carriers the estimated HRs were 0.29 (P = 0.007) for ever having had a live-birth and 0.72 (P = 0.08) per live-birth. The estimated HR associated with increments of 5 years in age at first birth was 0.58 (P = 0.03) for BRCA1 mutation carriers, 0.78 (P = 0.5) for BRCA2 mutation carriers and 0.65 (P = 0.04) for all carriers combined. It should be noted that there was likely to be over-fitting of these latter models due to the small number of affected women in this reduced sample set (37 and 16 for BRCA1 and BRCA2 mutation carriers, respectively).
Discussion
Parity and breast cancer risk
We have evaluated the effect of parity on the risk of breast cancer in 515 BRCA1 mutation carriers and 503 BRCA2 mutation carriers in Spain. After adjusting for study centre and year of birth, we observed evidence that parity is associated with protection from breast cancer in BRCA1 and BRCA2 mutation carriers. Each live-birth was associated with an estimated 13% risk reduction. We observed no evidence of an association with age at first birth. The results from previous studies of the possible effect of parity on breast cancer risk in BRCA1 and BRCA2 mutation carriers have been mixed. They are summarized in Table 4 . Jernstrom et al., [16] pooled data from carriers of mutations in both genes (although 80% had mutations in BRCA1) and found that parous carriers were at an estimate 71% increased risk of breast cancer compared with nulliparous carriers. They also observed a trend effect, with an estimated 24% increased risk per full-term pregnancy. This result was not replicated in a subsequent study by the same group, based on a much larger set of mutation carriers from 55 international collaborating centres [14] , most (73%) in North America. They observed that for women with a BRCA1 mutation, having four or more children was associated with reduced breast cancer risk compared with being nulliparous. In contrast, among BRCA2 carriers, increasing parity was associated with an increased risk of breast cancer (15% per live-birth). A third study by some of the same authors [15] , reported that for Polish BRCA1 mutation carriers, each live-birth was associated with an estimated 20% increased risk of breast cancer. All three studies matched unaffected carriers to affected carriers on year of birth, country and gene mutated and estimated odds ratios (OR) using condition logistic regression.
The IBCCS, a predominantly European consortium, has more recently published their analysis of parity as a potential modifier of breast cancer risk in mutation carriers [17] . They obtained similar results for carriers of mutations in BRCA1 and BRCA2. In a pooled analysis, they observed no effect associated with being parous, but among parous women, estimated that each live-birth was associated with a statistically significant 14% decrease in risk. This effect was only observed in women over age 40 years. This group also evaluated the effect of age at first live-birth and found marginally statistically significant evidence that it differed between BRCA1 and BRCA2 mutation carriers [17] . While for BRCA1 mutation carriers, having a child later in life appeared to be associated with protection, the opposite seemed to be the case for BRCA2 mutation carriers. Antoniou et al. [18] subsequently carried out a very similar analysis of a smaller set of mutation carriers from the United Kingdom and found that ever being parous was associated with an estimated 56% reduced risk for all mutation carriers combined, but again, only for women over age 40. For women of all ages, there was marginal evidence of a trend of decreasing risk with increasing parity. They also observed evidence that in parous BRCA2 mutation carriers, risk is higher for those who have their first child later. Both these studies estimated HR using weighted Cox regression, adjusting for year of birth and other covariates.
Two other studies have examined the effect of age at first birth on breast cancer risk in mutation carriers. Rebbeck et al. [20] studied mostly (83%) BRCA1 mutation carriers and observed that those who had their first birth earlier were at reduced risk of breast cancer. Most recently, members of the aforementioned international consortium applied their matched case-control design to the largest set of mutation carriers studied to date [19] . They found no evidence of an association for all carriers combined and reported that this result was consistent in stratified analyses by gene mutated.
Our results are consistent with those of the two other European studies that applied the same analytic approach [17, 23] . This approach allows all mutation carriers with complete data to be included, in contrast to the majority of the other studies in which up to 40% of carriers were excluded because no matched-pair was found [14, 19] . The consistent results from these three independent studies suggest that, as for women in the general population, parity is associated with protection from breast cancer for women at high risk of the disease due to mutations in BRCA1 and BRCA2. This finding may be particularly relevant to unaffected mutation carriers who are concerned about the impact pregnancy may have on their own breast cancer risk.
While our results are also consistent with there being no association between age at first birth and breast cancer risk in mutation carriers, the power of our study in this regard was limited (as discussed further, below), and the estimated HRs for trend are in the same (opposing) directions as those reported by the two European studies [17, 18] . It is therefore difficult to reach any definitive conclusions in this regard.
Parity and ovarian cancer risk
Regarding ovarian cancer risk, after adjusting for study centre and year of birth, we observed marginal evidence that for BRCA1 mutation carriers, ever having had a livebirth is associated with protection. We also observed that for parous BRCA1, and possibly BRCA2, mutation carriers, later age at first birth is associated with protection. Three studies have evaluated parity as a modifier of ovarian cancer risk in mutation carriers. A Polish study of 300 BRCA1 mutation carriers found no evidence of association with number of live-births [15] . The previously mentioned international consortium studied 3,223 mutation carriers, and observed that while women with BRCA1 mutations (84% of their sample) appeared to be protected from ovarian cancer both by ever having had full-term pregnancy (OR = 0.67, 95%CI = 0.46-0.96, P = 0.03) and with increasing parity (OR = 0.87 per birth, 95%CI = 0.79-0.95, P = 0.003), parous BRCA2 mutation carriers were at increased risk (OR = 2.74, 95%CI = 1.18-6.41, P = 0.02) [21] . The authors did not assess age at first birth as a risk modifier. Finally, the IBCCS has recently reported on their study of larger sample of 2,281 BRCA1 and 1,038 BRCA2 mutation carriers [22] . It also observed evidence that among parous BRCA1 mutation carriers, ovarian cancer risk decreased with each live-birth after the first (P = 0.002), but that risk was also reduced for those who were nulliparous, relative to those who had had just one live-birth (P = 0.02). No definitive conclusions were reached regarding the effect of parity for BRCA2 mutation carriers. No evidence of an association with ovarian cancer risk was seen for age at first birth.
Our finding that later age at first birth is associated with reduced risk of ovarian cancer in mutation carriers is consistent with what has been observed in the general population, based on two large [25, 26] (and a combined analysis of smaller [13] ) population-based case-control studies, although inconsistent findings have been reported from much smaller, hospital-based studies [13, 27, 28] . Further investigation is warranted to clarify this issue.
Study biases and limitations
Our study, like those of the IBCCS and the UK group [17, 18, 22] , sought to account for the potential biases inherent in these studies of a highly selected and related sample of mutation carriers by modelling time from birth to diagnosis of breast or ovarian cancer in carriers using weighted Cox regression. Weights were calculated to correct for the overrepresentation of affected individuals, assuming that the age-specific incidence rates for breast and ovarian cancer in carriers of mutations in both genes estimated by Antoniou et al. [1] are applicable [23] . Our recent study of the penetrance of mutations in BRCA1 and BRCA2 in Spanish multiple-case families indicated that this assumption is valid [5] . That our results were maintained after excluding prevalent cases suggests that survival bias was not present.
While we attempted to include obligate carriers wherever possible, in general, a mutation carrier had to be genetically tested in order to be included in the analysis. A further potential bias in this study would therefore be present if affected and unaffected women were influenced by parity in different ways in terms of their decision to undergo genetic testing. It may be, for example, that women who have already been diagnosed with breast or ovarian cancer are more influenced in this decision by whether or not they have children (at potential genetic risk of the disease), than are unaffected women and this may result in bias in HR estimation. However, it could be hypothesized that this would tend to bias HR estimates in the direction of increased risk associated with being parous, rather than towards the observed protection.
One of the limitations of our study was that we measured time to cancer diagnosis and age at first birth in years, rather than months or days. This would have reduced the power to detect associations, but is unlikely to have introduced bias in HR estimation. Another potential limitation was that we were not able to adjust for potential confounding factors such as education level and other hormonal risk factors because we did not systematically collect this information on all mutation carriers. However, other studies were able to adjust for most of these factors and found that this had little impact on parity-associated HR estimates for breast and ovarian cancer [17, 21] . Finally, the number of mutation carriers with ovarian cancer was relatively low, particularly with regard to BRCA2, and so the corresponding results should be interpreted with greater caution.
Conclusions
This is the third independent study to find that, as in the general population, parity appears to be associated with protection from breast cancer in women with mutations in BRCA1 and BRCA2. Nevertheless, results have not been consistent across all studies and their retrospective designs imply a number of potential biases. Prospective studies of mutation carrier cohorts are therefore likely to be highly informative in this regard.
Parity also appears to confer protection from ovarian cancer, at least for BRCA1 mutation carriers. Whether this is the case for BRCA2 mutation carriers remains to be confirmed. It may be that later age at first birth is associated with protection from ovarian cancer in both BRCA1 and BRCA2 mutation carriers, as has been observed in the general population, but again, this finding requires confirmation in independent studies.
